chronic hepatitis C
Hepatology · 2005–2020
32decisions
20medicines
11carried consumer input
1,112individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| glecaprevir/pibrentasvir Treatment of chronic hepatitis C infection (genotypes 1-6) in patients who are treatment-naïve with compensated cirrhosis. | Dec 2020 | Deferred | none received |
| direct-acting antiviral (DAA) regimens Changes to listings of direct-acting antiviral regimens for the treatment of chronic hepatitis C infection, including modifications to prescribing requirements… | Mar 2019 | Recommended | no section in document |
| This is a surveillance/data collection progress report on direct-acting antiviral (DAA) medicines for chronic hepatitis C treatment, not an assessment of a… | Mar 2019 | Noted | no section in document |
| sofosbuvir with velpatasvir and voxilaprevir Treatment of adult patients with chronic hepatitis C who have received prior treatment with an NS5A-based treatment regimen and not achieved sustained… | Mar 2018 | Deferred | input received Hepatitis Australia |
| glecaprevir with pibrentasvir Treatment of chronic hepatitis C infection for patients with genotypes 1-6, with or without cirrhosis, in NS5A treatment naïve patients. | Jul 2017 | Deferred | input received |
| glecaprevir with pibrentasvir Treatment of chronic hepatitis C virus (HCV) infection in patients with genotypes 1-6, including those who have failed prior NS5A inhibitor treatment, with or… | Nov 2017 | Recommended | input received |
| grazoprevir / elbasvir Treatment of chronic hepatitis C infection in patients with genotypes 1, 4 or 6 (treatment-naïve and treatment-experienced), and genotype 3 treatment-naïve… | Jul 2016 | Recommended with restriction | 6 individuals Hepatitis Australia · AIDS Association · Australian Hepatology Association · Haemophilia Foundation Australia |
| ribavirin Treatment of chronic hepatitis C (CHC) infection, specifically genotype 3 CHC in cirrhotic patients (both treatment naïve and treatment experienced), in… | Jul 2016 | Recommended with restriction | none received |
| ribavirin Chronic hepatitis C infection (CHC) in combination therapy with other oral agents. The submission requested PBS listing of an additional 200 mg tablet strength. | Jul 2016 | Recommended | none received |
| simeprevir Treatment of chronic hepatitis C (CHC) infection in combination with other antivirals. This submission concerns a change in listing restrictions from Section… | Mar 2016 | Recommended with restriction | no section in document |
| paritaprevir/ritonavir/ombitasvir/dasabuvir Treatment of patients with genotype 1 chronic hepatitis C (CHC) infection who have compensated liver disease, irrespective of previous treatment history. | Jul 2015 | Recommended with restriction | 114 individuals |
| ribavirin Treatment of adults with chronic hepatitis C genotype 2 or 3 in combination with sofosbuvir, for both treatment-naïve and treatment-experienced patients, as… | Jul 2015 | Recommended with restriction | 78 individuals |
| simeprevir Treatment of patients with genotype 1 chronic hepatitis C infection who have compensated liver disease, irrespective of previous treatment history, in… | Jul 2015 | Deferred | 78 individuals |
| asunaprevir Treatment of chronic hepatitis C virus (HCV) genotype 1b infection in combination with daclatasvir. | Mar 2015 | Not recommended | 172 individuals Gastroenterological Society of Australia |
| ribavirin Treatment of chronic hepatitis C (genotypes 2 and 3) in combination with sofosbuvir in treatment-naïve patients with compensated liver disease. | Mar 2015 | Not recommended | 172 individuals Gastroenterological Society of Australia |
| sofosbuvir Treatment of chronic hepatitis C (CHC) in treatment-naïve and treatment-experienced patients with genotypes 1-6, administered in combination with peginterferon… | Mar 2015 | Recommended with restriction | 231 individuals Gastroenterological Society of Australia |
| daclatasvir Treatment of chronic hepatitis C infection across all genotypes, irrespective of previous treatment history or cirrhosis status, in combination with sofosbuvir. | Nov 2015 | Recommended with restriction | none received |
| ribavirin Treatment of adults with chronic hepatitis C (CHC) genotype 2 or 3 infection in combination with direct acting antivirals (DAAs), particularly sofosbuvir. | Nov 2015 | Recommended | no section in document |
| simeprevir Treatment of patients with genotype 1 chronic hepatitis C infection who have compensated liver disease, in combination with sofosbuvir, irrespective of… | Nov 2015 | Recommended with restriction | no section in document |
| sofosbuvir Treatment of chronic hepatitis C (CHC) in treatment-naïve patients with genotypes 1-6, treatment-naïve patients with genotypes 1-3 unsuitable for… | Jul 2014 | Not recommended | 261 individuals Australian Liver Association |
| boceprevir Treatment of chronic hepatitis C genotype 1 infection in combination with peginterferon alfa and ribavirin in adult patients (18 years or older) with… | Mar 2012 | Recommended with restriction | unclear |
| boceprevir Treatment of chronic hepatitis C genotype 1 infection in patients 18 years or older with compensated liver disease who are treatment naïve or who have failed… | Mar 2012 | Recommended with restriction | unclear |
| telaprevir Treatment of chronic genotype 1 hepatitis C in combination with peginterferon-alfa and ribavirin in patients 18 years or older with compensated liver disease… | Mar 2012 | Recommended with restriction | unclear |
| boceprevir, ribavirin, peginterferon alfa-2b Treatment of chronic hepatitis C genotype 1 infection in adult patients (18 years and older) with compensated liver disease who are treatment naïve or who have… | Nov 2012 | Not recommended | no section in document |
| boceprevir Treatment of chronic hepatitis C genotype 1 infection in combination with peginterferon alfa and ribavirin in adult patients (18 years and older) with… | Jul 2011 | Not recommended | unclear |
| ribavirin and peginterferon alfa-2b Treatment of chronic hepatitis C in children and adolescents with a body weight of 27 kg or greater with compensated liver disease who have not received… | Jul 2011 | Recommended with restriction | no section in document |
| peginterferon alfa-2a / ribavirin Treatment of chronic hepatitis C in patients aged 18 years or older with compensated liver disease who have failed one prior attempt at interferon-based… | Jul 2010 | Recommended with restriction | no section in document |
| peginterferon alfa-2a and ribavirin Treatment of chronic hepatitis C in patients aged 18 years or older with compensated liver disease who have failed one prior attempt at interferon-based… | Jul 2010 | Recommended with restriction | no section in document |
| ribavirin and peginterferon alfa-2b Treatment of chronic hepatitis C in patients who have failed one prior attempt at interferon-based therapy (non-pegylated or pegylated). | Jul 2008 | Recommended | no section in document |
| ribavirin and peginterferon alfa-2b Treatment of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who have received no more than one prior attempt at… | Jul 2008 | Recommended | no section in document |
| peginterferon alfa-2b; ribavirin Treatment of chronic hepatitis C in patients who have not previously received interferon treatment, with removal of the liver biopsy requirement for… | Nov 2005 | Recommended with restriction | no section in document |
| peginterferon alfa-2b and ribavirin Treatment of chronic hepatitis C in patients with no or mild hepatitis C (fibrosis stages F0-F1/A0-A1), removing the requirement for liver biopsy to establish… | Nov 2005 | Recommended with restriction | no section in document |
Who spoke
Gastroenterological Society of Australia · Hepatitis Australia · AIDS Association · Australian Hepatology Association · Haemophilia Foundation Australia · Australian Liver Association
What the PBS pays
$481M in government benefit over 2024–25, across 68,261 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| sofosbuvir | $156.9M |
| sofosbuvir with velpatasvir and voxilaprevir | $156.9M |
| glecaprevir with pibrentasvir | $145.2M |
| peginterferon alfa-2a and ribavirin | $11M |
| peginterferon alfa-2a, ribavirin | $11M |
| paritaprevir / ritonavir / ombitasvir / dasabuvir | $0.3M |
Appraised elsewhere
NICE, in England and Wales, has appraised 11 technologies for this condition, recommending 11 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| sofosbuvir velpatasvir voxilaprevirSofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C | TA507 | recommended restricted | 2018-02 |
| glecaprevir pibrentasvirGlecaprevir–pibrentasvir for treating chronic hepatitis C | TA499 | recommended restricted | 2018-01 |
| sofosbuvir velpatasvirSofosbuvir–velpatasvir for treating chronic hepatitis C | TA430 | recommended restricted | 2017-01 |
| elbasvir grazoprevirElbasvir–grazoprevir for treating chronic hepatitis C | TA413 | recommended restricted | 2016-10 |
| ledipasvir sofosbuvirLedipasvir–sofosbuvir for treating chronic hepatitis C | TA363 | recommended | 2015-11 |
| ombitasvir paritaprevir ritonavirOmbitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C | TA365 | recommended restricted | 2015-11 |
| sofosbuvirSofosbuvir for treating chronic hepatitis C | TA330 | recommended restricted | 2015-02 |
| peginterferon alfa and ribavirinPeginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people | TA300 | recommended | 2013-11 |
| peginterferon alfa and ribavirinPeginterferon alfa and ribavirin for the treatment of chronic hepatitis C | TA200 | recommended | 2010-09 |
| peginterferon alfa and ribavirinPeginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C | TA106 | recommended | 2006-08 |
| interferon alfa and ribavirinInterferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C | TA75 | recommended | 2004-01 |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| peginterferon alfaPEGASYS peginterferon alfa-2a 135 micrograms/0.5mL injection pre-fille | 2003 | 2 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 11 of 20 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.